# 臨床検査市場

> 臨床検査市場調査報告書：ラボの種類（剛性および柔軟性）、検査の種類（完全血球計算（CBC）、基本的な代謝パネル（BMP）、HbA1c検査、HGB/HCT検査、包括的な代謝パネル検査、BUNクレアチニン検査、腎パネル検査、電解質検査、肝パネル検査および脂質パネル検査）、アプリケーション（寄生虫学、ウイルス学、血液学、毒物学、免疫学/血清学、組織病理学および尿検査）、および地域（北アメリカ、ヨーロッパ、アジア太平洋、その他の地域） - 成長見通しおよび業界予測2025年から2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.82%
- **2024:** $ 123.27 Billion
- **2025:** $ 134.14 Billion
- **2035:** $ 312.37 Billion
- **Key Players:** Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMerieux (FR), PerkinElmer (US), Ortho Clinical Diagnostics (US) are some of the major participants in the global market.

**Report ID:** MRFR/LS/1118-CR · **Pages:** 88 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** October 05, 2026

**URL:** https://www.marketresearchfuture.com/reports/clinical-laboratory-test-market-1649

---

## Market Summary

Global Clinical Laboratory Test Market Size was valued at USD 123.27 Billion in 2024 & the market is projected to grow from USD 134.14 Billion in 2025 to USD 312.37 Billion by 2035, registering a CAGR of 8.80% during the forecast period 2025–2035. North America led the market with over 40.00% share, generating around USD 49.3 Billion in revenue.
 
The rising prevalence of chronic diseases, expanding aging population, and increasing emphasis on preventive healthcare are primary growth drivers for the Clinical Laboratory Test Industry. Growing adoption of advanced diagnostic technologies enables earlier disease detection, accurate monitoring, and improved clinical decision-making across healthcare systems.
 
According to the WHO Data Portal, noncommunicable diseases (NCDs) account for approximately 41 million deaths annually, representing nearly 74% of all global deaths, reinforcing the growing demand for clinical laboratory testing for early diagnosis, disease monitoring, and effective patient management.

## Market Drivers

### Growing Aging Population

The demographic shift towards an aging population is another significant factor influencing the global Market. As individuals age, they typically experience a higher incidence of health issues, necessitating more frequent laboratory testing. Projections indicate that by 2030, the number of people aged 65 and older will reach approximately 1.4 billion, which could lead to an increased demand for diagnostic services.
 
This demographic trend suggests that clinical laboratories will play a crucial role in managing the health of older adults, thereby driving growth in the Clinical Laboratory Test Market. The need for routine screenings and monitoring of age-related conditions is likely to further bolster this market.

- According to the World Bank, people aged 65 years and above account for more than 10% of the global population, driving sustained demand for routine laboratory diagnostics, chronic disease monitoring, and preventive health screening services.

### Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer appears to be a primary driver for the global Market. As these conditions require regular monitoring and management, the demand for laboratory tests is likely to rise. According to recent statistics, chronic diseases account for approximately 70% of all deaths, underscoring the necessity for effective diagnostic tools.
 
This trend suggests that healthcare providers are increasingly relying on clinical laboratory tests to guide treatment decisions and improve patient outcomes. Consequently, the market is expected to experience substantial growth as healthcare systems adapt to the rising burden of chronic diseases.

- According to IHME, noncommunicable diseases remain the leading contributors to global disability and mortality, substantially increasing the requirement for routine clinical laboratory testing for diagnosis, treatment monitoring, and disease management.

### Increased Focus on Preventive Healthcare

There is a growing emphasis on preventive healthcare, which is significantly impacting the global Market. As healthcare systems shift from reactive to proactive approaches, the demand for routine laboratory tests is expected to rise. Preventive screenings and early detection of diseases can lead to better health outcomes and reduced healthcare costs.
 
Reports indicate that investments in preventive care can save healthcare systems billions annually. This trend suggests that clinical laboratories will increasingly be utilized for preventive measures, thereby driving growth in the market. The integration of laboratory tests into routine health assessments is likely to become more commonplace.

- According to PubMed, preventive laboratory screening programs significantly improve early disease detection and clinical outcomes while reducing long-term healthcare costs through timely intervention and risk management.

### Technological Innovations in Diagnostics

Technological advancements in diagnostic tools and methodologies are transforming the global Market. Innovations such as next-generation sequencing, automated analyzers, and point-of-care testing devices are enhancing the accuracy and efficiency of laboratory tests. These technologies not only improve diagnostic capabilities but also reduce turnaround times, which is critical in clinical settings.
 
The market for laboratory automation is projected to grow significantly, with estimates suggesting a compound annual growth rate of over 6% in the coming years. This trend indicates that as technology continues to evolve, the market will likely expand, driven by the demand for more sophisticated and rapid testing solutions.

- According to PubMed, laboratory automation and next-generation molecular diagnostics have demonstrated improved analytical accuracy, shorter turnaround times, and increased testing efficiency across modern clinical laboratories.

### Regulatory Support for Laboratory Testing

Regulatory frameworks supporting laboratory testing are also contributing to the growth of the global Market. Governments and health organizations are recognizing the importance of laboratory diagnostics in disease management and public health. Initiatives aimed at improving laboratory standards and accessibility are being implemented, which may enhance the reliability of test results.
 
Furthermore, regulatory bodies are increasingly approving new tests and technologies, facilitating market entry for innovative solutions. This supportive environment suggests that the market will continue to thrive as regulatory measures promote the adoption of advanced diagnostic tools and methodologies.

- According to the World Bank, increasing public healthcare investments continue strengthening diagnostic infrastructure, supporting broader implementation of advanced laboratory testing technologies and improving healthcare accessibility worldwide.

## Future Outlook

臨床検査市場規模は2035年までに3123.7億米ドルに達する見込みで、8.8%のCAGRで成長しています。

**New opportunities:**

- 遠隔診断のためのテレヘルスサービスの拡大 個別化医療検査キットの開発 AI駆動のラボ自動化ソリューションへの投資

2035年までに、市場は革新と需要の増加により堅調であると予想されています。

## Segment Insights

The application segment shows a varied distribution among several critical areas. [Immunology](https://www.marketresearchfuture.com/reports/immunology-market-30261)/serology holds the largest market share of 29% due to the increasing prevalence of autoimmune diseases and the growing demand for specialized diagnostics. Other segments such as hematology and virology also contribute significantly but trail behind in terms of overall share. Toxicology, though smaller in comparison, is gaining traction as more laboratories focus on substance abuse testing and environmental monitoring.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America leads in the Clinical Laboratory Test Market, accounting for over 39.99% of the global revenue in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of [chronic diseases](https://www.marketresearchfuture.com/reports/chronic-disease-management-market-981), and a strong emphasis on research and development. Regulatory support from agencies like the FDA further catalyzes innovation and adoption of new testing technologies.

- According to the CDC, 6 in 10 U.S. adults live with at least one chronic disease, while 4 in 10 have two or more, substantially increasing demand for routine laboratory diagnostics, disease monitoring, and preventive screening programs across North America.

The United States is the primary contributor, with significant investments from key players such as Abbott Laboratories and Thermo Fisher Scientific. Canada also plays a vital role, focusing on enhancing laboratory capabilities. The competitive landscape is characterized by a mix of established companies and emerging startups, fostering a dynamic environment for clinical testing advancements.

- GE HealthCare invested approximately USD 1.9 billion in research and development during 2024, supporting continued innovation in diagnostic technologies, laboratory workflow optimization, and precision healthcare solutions across North America.

### Europe : Regulatory Framework Enhancements

Europe Clinical Laboratory Test Market was valued at USD 36.98 billion in 2024, making it the second-largest regional market with a 30% share. The region benefits from stringent regulatory frameworks that ensure high-quality testing standards. The European Union's In Vitro Diagnostic Regulation (IVDR) is a significant catalyst, promoting innovation while ensuring patient safety and efficacy in testing. 

- The European Medicines Agency (EMA) coordinates scientific evaluation of medicines across 27 European Union Member States, supporting robust regulatory standards that encourage innovation, diagnostic quality, and patient safety throughout Europe's clinical laboratory testing ecosystem.

Leading countries include Germany, France, and the UK, where major players like Roche Diagnostics and Siemens Healthineers are headquartered. The competitive landscape is robust, with a mix of multinational corporations and local firms. The focus on personalized medicine and advanced diagnostics is driving growth, supported by government initiatives to enhance healthcare delivery.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is an emerging powerhouse in the market, holding approximately 25% of the global market share. The region's growth is fueled by increasing healthcare expenditure, rising awareness of preventive healthcare, and a growing population. Countries like China and India are witnessing rapid advancements in healthcare infrastructure, which are pivotal for market expansion.

China is the largest market in the region, driven by significant investments in healthcare technology and a rising demand for diagnostic services. India follows closely, with a burgeoning private healthcare sector. The competitive landscape features both global players and local companies, creating a diverse market environment that fosters innovation and accessibility in clinical testing.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is characterized by untapped market potential in the clinical laboratory test sector, holding about 5% of the global market share. Growth is driven by increasing investments in healthcare infrastructure, government initiatives to improve healthcare access, and rising awareness of disease prevention. Countries like the UAE and South Africa are leading the way in enhancing laboratory capabilities and services.

The competitive landscape is evolving, with both international and local players entering the market. Key players are focusing on partnerships and collaborations to expand their reach. The region's unique challenges, such as varying regulatory environments, present opportunities for innovation and tailored solutions in clinical testing.

## Competitive Benchmarking

The global industry is characterized by a dynamic competitive landscape, driven by technological advancements, increasing demand for diagnostic testing, and a growing emphasis on personalized medicine. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Abbott Laboratories (US) focuses on innovation in point-of-care testing, while Roche Diagnostics (CH) emphasizes its extensive portfolio in [molecular diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171). Siemens Healthineers (DE) is investing heavily in digital transformation, integrating AI and data analytics into its testing solutions.
 
Collectively, these strategies not only enhance operational efficiency but also foster a competitive environment that prioritizes rapid technological advancements and improved patient outcomes. Key business tactics within the global industry include localizing manufacturing and optimizing supply chains to enhance responsiveness to regional demands. The market structure appears moderately fragmented, with a mix of large multinational corporations and smaller specialized firms. The collective influence of key players shapes the competitive dynamics, as they leverage their resources to innovate and expand their market reach, thereby intensifying competition.
 
In August 2025, Roche Diagnostics (CH) announced the launch of its new [digital pathology](https://www.marketresearchfuture.com/reports/digital-pathology-market-1955)platform, which integrates AI capabilities to streamline the diagnostic process. This strategic move is significant as it positions Roche at the cutting edge of digital health solutions, potentially improving diagnostic accuracy and efficiency. The integration of AI into pathology could redefine workflows in laboratories, making Roche a formidable competitor in the market.
 
In September 2025, Siemens Healthineers (DE) unveiled a partnership with a leading telehealth provider to enhance remote diagnostic capabilities. This collaboration is crucial as it reflects a growing trend towards telemedicine, allowing for more accessible and timely laboratory testing. By aligning with telehealth services, Siemens Healthineers is likely to expand its customer base and improve patient engagement, thereby solidifying its market presence.
 
In July 2025, Abbott Laboratories (US) expanded its manufacturing capabilities in Asia to meet the rising demand for rapid testing solutions. This expansion is strategically important as it not only increases production capacity but also reduces lead times for customers in the region. By localizing manufacturing, Abbott can respond more swiftly to market needs, enhancing its competitive edge in a rapidly evolving landscape.
 
As of October 2025, current competitive trends in the market are heavily influenced by digitalization, sustainability initiatives, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized healthcare solutions.

## Recent News & Developments

September 2026, Siemens Healthineers announced the global launch of Innovance D-Dimer 2.0, which carries FDA 510(k) clearance and CE mark status. The assay helps clinicians exclude deep vein thrombosis and pulmonary embolism in outpatients and is built for fast STAT testing in the lab. It widens Siemens' coagulation menu in a time-critical use case. (Source: [clpmag.com](https://clpmag.com/disease-states/cardiovascular/siemens-healthineers-fda-cleared-d-dimer-blood-test-launch/))

September 2026, Cepheid received FDA clearance for the Xpert Respiratory panel, a multiplex PCR test that detects 13 common viral and bacterial respiratory pathogens from a single nasopharyngeal swab. It runs on the GeneXpert platform. The clearance gives Danaher a broader syndromic respiratory test on a widely installed platform. (Source: [captodayonline.com](https://www.captodayonline.com/fda-clears-cepheid-xpert-respiratory-panel/))

September 2026, bioMérieux's BioFire Respiratory 2.1 Plus and BioFire FilmArray Pneumonia Plus panels received the CE mark under the IVDR as class D devices, the highest risk class. The classification is driven by the inclusion of MERS-CoV on both menus. bioMérieux says it is among the first companies to receive this certification for multiplex syndromic tests that include MERS-CoV. The IVDR-certified panels are expected on the European market early next year. This secures EU market access for two flagship syndromic panels. (Source: [captodayonline.com](https://www.captodayonline.com/biofire-respiratory-panels-get-ivdr-class-d-ce-mark/))

## Report Scope

| MARKET SIZE 2024 | 123.27(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 134.14(USD Billion) |
| MARKET SIZE 2035 | 312.37(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMerieux (FR), PerkinElmer (US), Ortho Clinical Diagnostics (US) |
| Segments Covered | Typess of Laboratories, Typess of Tests, Applications, Region |
| Key Market Opportunities | Integration of artificial intelligence in diagnostic processes enhances efficiency in the market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: 2025年の臨床検査市場の現在の評価額はどのくらいですか？**
A: 臨床検査市場は2024年に約123.27億米ドルと評価されています。

**Q: 2035年までの臨床検査市場の予測市場規模はどのくらいですか？**
A: 市場は2035年までに約312.37億米ドルに達すると予測されています。

**Q: 2025年から2035年の予測期間中の臨床検査市場の期待CAGRはどのくらいですか？**
A: 2025年から2035年の予測期間中の臨床検査市場の期待CAGRは8.82%です。

**Q: 臨床検査市場で主要なプレーヤーと見なされる企業はどれですか？**
A: 市場の主要なプレーヤーには、アボットラボラトリーズ、ロシュダイアグノスティックス、シーメンスヘルスケア、サーモフィッシャーサイエンティフィックが含まれます。

**Q: 臨床検査市場の主要なセグメントは何ですか？**
A: 主要なセグメントには、ラボの種類、テストの種類、アプリケーションが含まれます。

**Q: 市場における剛性ラボと柔軟ラボの評価はどのように比較されますか？**
A: 2024年には、剛性ラボは49.31億米ドル、柔軟ラボは73.96億米ドルと評価されました。

**Q: 2025年の完全血球計算（CBC）検査の市場評価はどのくらいですか？**
A: 完全血球計算（CBC）検査の市場評価は20.0億米ドルから50.0億米ドルの範囲になると予想されています。

**Q: 2035年までの免疫学/血清学アプリケーションの予測市場規模はどのくらいですか？**
A: 免疫学/血清学アプリケーションの予測市場規模は、2035年までに25.0億米ドルから60.0億米ドルに達すると予想されています。

**Q: 臨床検査市場における血液学アプリケーションの期待される成長トレンドは何ですか？**
A: 血液学アプリケーションは大幅に成長すると予測されており、市場評価は30.0億米ドルから75.0億米ドルの範囲になると期待されています。

**Q: 2025年の肝パネル検査と脂質パネル検査の評価はどのように比較されますか？**
A: 2024年には、肝パネル検査と脂質パネル検査はそれぞれ6.27億米ドルから19.37億米ドルの範囲で評価されました。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/clinical-laboratory-test-market-1649*